Denver – Researchers presenting at the Conference on Retroviruses and Opportunistic Infections (CROI) this week announced that one-third of children born with HIV who began antiretroviral therapy (ART) within 21 days of birth were able to maintain undetectable viral loads for at least 12 weeks after stopping treatment.
The study monitored 19 children with HIV, all of whom initiated ART very early in life. Findings indicate a potential pathway toward ART-free remission in a subset of these children, offering a significant advancement in the treatment of pediatric HIV. The results suggest that early intervention with ART may allow for long-term control of the virus, even after treatment is discontinued.
Even as more than 50% of perinatally HIV-infected children historically died before the age of two without treatment, early ART has dramatically improved outcomes, increasing both immune health and child survival rates, according to research published in Current HIV/AIDS Reports. However, the necessitate for lifelong ART presents challenges, including potential side effects and adherence difficulties.
The recent findings build on a growing body of evidence suggesting that very early ART initiation can lead to sustained viral control. A study published in The Lancet HIV demonstrated that ART-free remission for at least 48 weeks is achievable in children with in-utero HIV-1 infection who received very early ART. Researchers emphasize the importance of close monitoring for viral rebound and acute retroviral syndrome during ART interruption.
The potential for ART-free remission observed in these studies is particularly promising given that the research was conducted in resource-constrained countries, highlighting the feasibility of implementing early HIV testing at birth and initiating ART promptly. This approach could significantly limit the long-term burden of HIV infection in vulnerable populations.
Researchers continue to investigate the immunological mechanisms underlying these successful outcomes, exploring the potential of immune therapeutics to achieve viral remission and a functional cure for pediatric HIV. Further studies are planned to determine the long-term durability of ART-free remission and to identify the factors that predict which children are most likely to benefit from this approach.
